Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nepafenac - Alcon Research

Drug Profile

Nepafenac - Alcon Research

Alternative Names: AL-6515; Ilevro; Nepafenac ophthalmic suspension 0.1% - Alcon; Nevanac

Latest Information Update: 15 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon
  • Class Analgesics; Aniline compounds; Benzeneacetamides; Benzophenones; Eye disorder therapies; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain; Retinal oedema
  • Phase III Diabetic retinopathy

Most Recent Events

  • 09 Apr 2019 Novartis completed the spin-off of Alcon
  • 07 Nov 2018 Launched for Ocular inflammation in Hungary, France, Spain (Topical)
  • 07 Nov 2018 Launched for Ocular pain in Hungary, Spain, France (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top